News 
Market Data 
Discover
Replies to post #298539 on Innovation Pharmaceuticals Inc (IPIX)
Outstanding post. As IPIX shareholders are close to discovering the results of Brilacidin's effects on Covid 19 infected human respiratory epithelial cells it is important to have perspective on how to define success.
Even though we have waited months to reach this point it is important to outline the results for other Covid 19 drug trials to date.
Hydroxychloroquine has failed to show consistent results.
Ebola drugs Lopinavir and ritonavir showed no effect
Favipiravir a Japanese influenza drug has had mixed results in studies and is in a late stage trial in India
Invermectim has shown some reports of success, but its pharmacokinetics have come into question which may limit its usefulness
Remdesivir came in second to Regeneron's Z-mapp with Ebola. Gilead has skillfully guided it through all the political {both domestic and international} hoops to push it to the front of Dr Fauci's line only have it disappoint in the last Covid 19 trial when it was shown only to be mildly effective in patients receiving oxygen.
Anti-inflammatory drugs tocizumab and Kevzara have some benefit in patient with pulomonary complications.
https://www.medscape.com/viewarticle/930588#vp_3
https://emedicine.medscape.com/article/2500116-overview#a3
Vaccines for RNA viruses are notoriously difficult to develop and often take years, if ever. Where are the vaccines for AIDS and hepatitis C?
What about adenovirus, the most common cause of the common cold? Then there is the influenza vaccine. How effective is it...some years as little as 20%-30%.
In summary a knock out drug for Covid 19 does not exist. Most likely combination treatments of 2,3 or more drugs may be needed. Drugs with modest benefits will be directed to expedited FDA studies and early approval.
Brilacidin is unique. As outlined in the last communication no drug on the above list has all the characteristics of Brilacidin. It may have 3 antiviral mechanisms: 1. viral envelope or capsid giving it a virucidal ability 2. M-protein anti protease which limits viral replication and 3 a S protein ability to stop virus attachment. In addition its in vitro tests suggest an immunomodulating effects similar to Tocilizumab and Kevzara. Lastly is is a broad spectrum antibiotic.
www.ipharminc.com/new-blog/2020/5/21/brilacidin-for-covid-19-proposed-targets-and-mechanisms-of-action-against-sars-cov-2
"1) Antiviral—Virucidal Property (pre-infection, disrupting the viral envelope/destroying the virus)
2) Antiviral—Blocking Property (pre-infection, preventing viral attachment/viral entry to host cells)
3) Antiviral—Inhibitory Property (post-infection, interfering with viral replication intracellularly)
4) Anti-Inflammatory Property (post-infection, suppressing IL-6 and other pro-inflammatory mediators implicated in Severe Acute Respiratory Syndrome)
5) Anti-Bacterial Property (post-infection, helping to resolve secondary infections that can affect up to 20 percent of COVID-19 patients)"
IPIX investors should be optimistic about our chances to proceed to clinical trials. First Brilacidin is unique with multiple mechanisms of action. If you were going to design a drug to fight Covid 19 these are the characteristics you would seek.
Second our competition is not performing. Our trials have been delayed since Brilacidin was not an approved drug, but now it may be our turn.
The bar for success is low and Brilacidin could be a key treatment for Covid 19. We will just need to be a little more patient and wait for the test results.
JMO Farrell
05/30/20 2:45 PM
